ACADIA Pharmaceuticals (NASDAQ:ACAD) Issues Quarterly Earnings Results, Beats Expectations By $0.11 EPS

ACADIA Pharmaceuticals (NASDAQ:ACAD) released its earnings results on Wednesday. The biopharmaceutical company reported $0.31 earnings per share for the quarter, topping analysts’ consensus estimates of $0.20 by $0.11, FiscalAI reports. ACADIA Pharmaceuticals had a return on equity of 9.03% and a net margin of 33.42%. The firm had revenue of $342.30 million during the quarter, compared to the consensus estimate of $332.58 million. During the same period in the prior year, the firm posted $0.42 earnings per share. The firm’s revenue for the quarter was up 22.8% compared to the same quarter last year.

Here are the key takeaways from ACADIA Pharmaceuticals’ conference call:

• ACADIA reported $342 million in Q3 revenue, up 22% year over year on an adjusted basis. DAYBUE sales reached a record $140 million, up 39%, while NUPLAZID generated $202 million, up 12%; growth for both brands was largely volume-driven.
• ACADIA raised its 2026 DAYBUE sales guidance to $505 million–$520 million, citing STIX momentum, with more than half of U.S. patients using the formulation by quarter-end. The company also highlighted its Germany launch and a newly allowed U.S. patent expected to protect both formulations through March 2041, while reiterating its $700 million sales ambition for 2028.
• NUPLAZID guidance was narrowed to $760 million–$775 million, with management citing the time needed for its expanded sales force to build prescribing relationships. ACADIA maintained its ambition of approximately $1 billion in NUPLAZID sales by the end of 2028.
• The phase II RADIANT trial of remlifanserin in Alzheimer’s disease psychosis narrowly missed statistical significance on its primary endpoint (p=0.0603), although the 60 mg dose showed activity across four efficacy scales and a nominally significant result on a key secondary endpoint. ACADIA plans to advance the 60 mg dose and adjust trial conduct and statistical methods for phase III; the primary endpoint remains unchanged.
• ACADIA expects phase II results for remlifanserin in Lewy body dementia psychosis and for ACP-211 in major depressive disorder in the second half of 2027, extending the timeline for pipeline updates. The company ended the quarter with $976 million in cash.

ACADIA Pharmaceuticals Price Performance

ACADIA Pharmaceuticals stock traded up $0.40 during midday trading on Thursday, reaching $21.87. The stock had a trading volume of 751,745 shares, compared to its average volume of 1,723,695. ACADIA Pharmaceuticals has a twelve month low of $18.39 and a twelve month high of $30.96. The firm has a market cap of $3.77 billion, a price-to-earnings ratio of 9.88 and a beta of 0.87. The firm’s fifty day simple moving average is $23.20 and its two-hundred day simple moving average is $23.64.

Insider Activity

In other news, EVP Mark Schneyer sold 3,321 shares of the firm’s stock in a transaction on Friday, October 30th. The stock was sold at an average price of $20.88, for a total value of $69,342.48. Following the completion of the sale, the executive vice president owned 71,322 shares of the company’s stock, valued at $1,489,203.36. This trade represents a 4.45% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. 26.20% of the stock is owned by insiders.

Analyst Ratings Changes

A number of equities research analysts have weighed in on the stock. HC Wainwright cut their price target on shares of ACADIA Pharmaceuticals from $37.00 to $33.00 and set a “buy” rating for the company in a report on Friday, September 25th. Citizens Jmp cut their target price on shares of ACADIA Pharmaceuticals from $36.00 to $33.00 and set a “market outperform” rating for the company in a research note on Friday, September 25th. Royal Bank Of Canada reduced their target price on shares of ACADIA Pharmaceuticals from $37.00 to $36.00 and set an “outperform” rating for the company in a report on Thursday, October 8th. Oppenheimer restated a “market perform” rating on shares of ACADIA Pharmaceuticals in a research report on Wednesday, September 23rd. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $35.00 price target on shares of ACADIA Pharmaceuticals in a report on Monday, October 19th. Thirteen investment analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the stock. According to MarketBeat, ACADIA Pharmaceuticals presently has an average rating of “Moderate Buy” and an average price target of $31.34.

Key ACADIA Pharmaceuticals News

Here are the key news stories impacting ACADIA Pharmaceuticals this week:

• Positive Sentiment: ACADIA reported Q3 adjusted earnings of $0.31 per share, above consensus estimates of roughly $0.19–$0.20, and revenue of $342.3 million versus expectations of about $332.6 million. Revenue grew 22.8% year over year, providing a strong earnings catalyst. Zacks Q3 results article
• Positive Sentiment: Management cited continued momentum across DAYBUE and NUPLAZID, including strong U.S. DAYBUE performance and uptake of DAYBUE STIX. This supports the view that commercial growth is contributing to the revenue beat. Company Q3 results release
• Negative Sentiment: Wall Street Zen lowered its rating on ACAD to Hold, a more cautious signal that could limit enthusiasm, though the available report does not provide the rationale. Wall Street Zen rating report

ACADIA Pharmaceuticals Company Profile

ACADIA Pharmaceuticals Inc is a biopharmaceutical company focused on developing and commercializing medicines for central nervous system and neuropsychiatric disorders. The company’s research programs target conditions with significant unmet medical needs, including neurological and rare neurodevelopmental diseases.

ACADIA’s commercial products include NUPLAZID (pimavanserin), an atypical antipsychotic approved in the United States to treat hallucinations and delusions associated with Parkinson’s disease psychosis.